Thirty Madison

High-Level Overview

Thirty Madison is a healthcare technology company that operates a family of specialized brands delivering virtual care, personalized treatments, and medications for chronic conditions such as hair loss, migraines, acid reflux, allergies, skin conditions, and sexual health.[1][2][3] It serves patients seeking convenient access to condition-specific doctors and therapies, solving pain points like fragmented care, limited specialist availability, and barriers to treatment for ongoing issues by offering asynchronous telemedicine, back-office automation, and multidisciplinary care teams.[1][2] The company has demonstrated strong growth momentum, expanding from its initial Keeps brand for hair loss to multiple products, raising over $140M in Series C funding from investors like HealthQuest Capital and Johnson & Johnson, achieving unicorn status, and employing around 330 people with engineering as its largest team.[2][3][4]

Origin Story

Thirty Madison was founded in 2017 by Demetri Karagas and Steven Gutentag in New York City.[1][2] The idea emerged from identifying gaps in accessible care for common chronic conditions, starting with male pattern baldness via the Keeps brand, which connected users to licensed physicians for FDA-approved treatments through a web app.[1][3] Early traction came quickly with Keeps, leading to partnerships for scalable development from MVP stage; pivotal moments included launching Cove for migraines and Evens for acid reflux, raising a $47M Series B, and rapidly deploying an Urgent Care service during COVID-19 in 2020.[1][3] This evolution supported unicorn growth and expansion into more specialties.[3]

Core Differentiators

• Condition-Specific Brands: Operates focused brands like Keeps (hair loss), Cove (migraines), Evens (acid reflux), Picnic (allergies), Facet (skin), and NURX (sexual health), each tailored to unique patient needs with personalized treatments.[1][2][3]
• Proprietary Care Model: Combines asynchronous telemedicine, specialist physicians, shared nurses/coaches for ongoing support, and back-office tools for billing, escalations, and engagement, enabling scalable, lower-cost care.[1][2]
• Shared Infrastructure: Leverages centralized product, engineering, and marketing across brands to efficiently enter new chronic disease areas while maintaining specialist expertise.[1][3]
• Technology-Driven Scalability: Engineering-heavy team (98 employees) builds digital tools for consultations and automation, supporting rapid launches and growth from hair loss to broader conditions.[3][4]

Role in the Broader Tech Landscape

Thirty Madison rides the telemedicine and direct-to-consumer health wave, capitalizing on post-COVID demand for virtual, condition-focused care amid rising chronic disease prevalence and healthcare accessibility gaps.[1][2][3] Its timing aligns with regulatory shifts favoring telehealth and consumer preference for convenient, empathy-driven models over traditional systems.[2] Market forces like aging populations, underserved specialties, and investor interest in digital health (evidenced by $140M+ funding) propel it forward.[2][3] The company influences the ecosystem by proving scalable platforms can standardize care for "lower-risk" chronics, inspiring similar ventures and normalizing human-first, tech-enabled healthcare as a right.[1][3]

Quick Take & Future Outlook

Recent acquisition by Remedy Meds for $500M signals a pivot toward integration into a larger consumer health platform, potentially accelerating expansion.[5] Next steps likely include leveraging Remedy's pharmacy resources to cover more chronic conditions, as hinted in ambitions for comprehensive coverage.[3] Trends like AI-enhanced personalization and hybrid care models will shape its path, evolving its influence from niche disruptor to key player in unified chronic care ecosystems—building on its tech foundation to redefine accessible treatment at scale.[1][2][3][5]